Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy

Antiviral Research
Zuxiong HuangJinlin Hou

Abstract

Toll-like receptor 2 (TLR2) plays an important role in the immunopathogenesis of hepatitis B virus (HBV) infection. The relationship between TLR2 expression and clinical outcome of chronic HBV infection is not yet elucidated in details so far. Here, we employed clinical cohorts to investigate TLR2 expression and function in different phases of HBV infection and dynamic changes of TLR2 expression in HBeAg-positive chronic hepatitis B (CHB) patients during antiviral therapy. TLR2 was mainly expressed in monocytes and its ligand stimulation resulted in TNF-α, IL-6 and IL-10 production. Serum soluble TLR2 (sTLR2) levels were negatively correlated with TLR2 mRNA in PBMCs. As compared with immunotolerant carriers and inactive carriers, CHB patients showed an elevated TLR2 expression and TNF-α, IL-6 induction in PBMC, but had a decreased level of sTLR2 in serum. However, TLR2 expression and TNF-α induction in monocytes of CHB patients remained lower than healthy controls. Furthermore, higher TLR2 expression in PBMCs and lower level of sTLR2 in serum at baseline were predictive of a complete response to 52 weeks of telbivudine (LdT) therapy. Temporal dynamic analysis showed that TLR2 expression was restored with viral suppression and A...Continue Reading

References

May 14, 2005·Journal of Virology·Masanori IsogawaFrancis V Chisari
Feb 25, 2006·Cell·Shizuo AkiraOsamu Takeuchi
Sep 7, 2006·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·S M RiordanK Visvanathan
Dec 26, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kumar VisvanathanStephen Locarnini
Jan 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F Lok, Brian J McMahon
Feb 6, 2007·Seminars in Immunology·Taro Kawai, Shizuo Akira
Oct 12, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jun WuJoerg F Schlaak
Nov 28, 2007·Annual Review of Pathology·Luca G Guidotti, Francis V Chisari
Aug 13, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Alexander EvansNikolai V Naoumov
Mar 21, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Simon P FletcherStephan Menne
Apr 25, 2012·Gut·Maura Dandri, Stephen Locarnini
May 23, 2012·Expert Opinion on Drug Discovery·Xiaoyong ZhangMengji Lu
May 24, 2012·Journal of Hepatology·Xiaoyong ZhangMengji Lu
May 25, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yongyin LiJinlin Hou
Jul 23, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Barbara Rehermann, Antonio Bertoletti
Dec 23, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Carlo Ferrari

❮ Previous
Next ❯

Citations

Aug 18, 2016·Frontiers in Immunology·Bethany M HenrickKenneth Lee Rosenthal
Oct 23, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ejuan ZhangMengji Lu
Aug 9, 2020·Frontiers in Immunology·Jorge A SotoAlexis M Kalergis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.